NEUMORA THERAPEUTICS, INC.
Cash Flow History
| Fiscal Year | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| FY2023 | $-163.3M | $-163.4M | $117.0K | $17.2M |
| FY2024 | $-182.9M | $-182.9M | — | $40.0M |
| FY2025 | $-206.4M | $-206.4M | — | $29.9M |
Cash Flow History
| Fiscal Year | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| FY2023 | $-163.3M | $-163.4M | $117.0K | $17.2M |
| FY2024 | $-182.9M | $-182.9M | — | $40.0M |
| FY2025 | $-206.4M | $-206.4M | — | $29.9M |